Close this search box.

The popularity of flower right now

cannabis news looking at flower sales


America’s most popular cannabis category is losing its dominance

In its latest report, Headset conducted a deep dive on America’s most popular cannabis category: flower, reports MJBizDaily. And while it’s still the most popular category, consumer appetites are shifting.

Key insights

  • Flower is the largest cannabis product category, but sales increased by just 11.5% compared to overall cannabis sales, which grew by 18% in California, Colorado, Michigan, Nevada, Oregon and Washington
  • Flower prices have dropped by about $1/gram
  • Newer markets in the northeast are focused on THC potency
  • Retailers in more mature markets are seeing consumer interests shift away from potency and more toward terpenes and minor cannabinoids—and they’re willing to pay more for quality
  • Pre-rolls sales grew by 38.9%

The takeaway

While flower buyers are becoming more sophisticated, high-THC flower is still a winner, said Nick Sosiak, CFO of Quebec-based Cannara Biotech. “If you have the highest THC, you’ll beat all your competitors.”

Enjoy Cannabis Daily each morning at 7 a.m.


Tilray consolidates its medical brands

After acquiring Aphria last May, Tilray announced it is consolidating its medical brands under one umbrella called Tilray Medical, reports Green Market Report.

The details

  • Tilray launched a value, lower potency brand called Symbios shortly after acquiring Aphria last year
  • Aphria flower was guaranteed to test at 18% THC or higher
  • Aphria’s oils were full-spectrum, Symbios’s are distillate-based
  • Through Tilray Medical, medical cannabis consumers can access all four brands: Tilray, Aphria, Broken Coast and Symbios

The takeaway

Tilray has focused largely on global medical markets in recent months, expanding its product offerings in Australia in January. The company has 20 brands in more than 20 countries, according to a press release.


DanCann raises another £1 million to execute its ambitious strategy

Denmark-based medical cannabis company DanCann Pharma raised another £1 million, which will help the company bring its first products to market in 2022, writes BusinessCann.

The company’s plans include:

  • Integrating with CannGros, which they acquired for more than £15 million last fall
  • Bringing nine cultivars to market, carefully selected among 95 options
  • EU GMP certification of its cultivation facility
  • Entering the emerging German market

The takeaway

“The proceeds allow us to implement our plans with peace of mind in 2022 while keeping focus on the milestones that await us,” said CEO Jeppe Krog Rasmussen.

Related Posts

Related Posts


Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you


Browse by Tags




© 2023 Prohibition Holdings Ltd. All Rights Reserved.


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?